Pfizer Limited Fundamental Analysis (NSE: PFIZER.NS)
Pfizer Limited Fundamental Analysis (NSE: PFIZER.NS)
Pfizer Limited (NSE: PFIZER.NS) shows moderate financial fundamentals with a PE ratio of 29.28, profit margin of 28.67%, and ROE of 17.93%. The company generates $25.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 97.2/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze PFIZER.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentPFIZER.NS demonstrates superior asset utilization.
Valuation Score
ModeratePFIZER.NS shows balanced valuation metrics.
Growth Score
ModeratePFIZER.NS shows steady but slowing expansion.
Financial Health Score
ExcellentPFIZER.NS maintains a strong and stable balance sheet.
Profitability Score
ExcellentPFIZER.NS achieves industry-leading margins.
Key Financial Metrics
Is PFIZER.NS Expensive or Cheap?
P/E Ratio
PFIZER.NS trades at 29.28 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, PFIZER.NS's PEG of -4.98 indicates potential undervaluation.
Price to Book
The market values Pfizer Limited at 5.03 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 25.01 times EBITDA. This signals the market has high growth expectations.
How Well Does PFIZER.NS Make Money?
Net Profit Margin
For every $100 in sales, Pfizer Limited keeps $28.67 as profit after all expenses.
Operating Margin
Core operations generate 37.57 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $17.93 in profit for every $100 of shareholder equity.
ROA
Pfizer Limited generates $14.68 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Pfizer Limited produces operating cash flow of $5.99B, showing steady but balanced cash generation.
Free Cash Flow
Pfizer Limited generates strong free cash flow of $5.89B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $128.78 in free cash annually.
FCF Yield
PFIZER.NS converts 2.79% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.28
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-4.98
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.03
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.39
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.06
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.18
vs 25 benchmark
ROA
Return on assets percentage
0.15
vs 25 benchmark
ROCE
Return on capital employed
0.22
vs 25 benchmark
How PFIZER.NS Stacks Against Its Sector Peers
| Metric | PFIZER.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.28 | 29.04 | Neutral |
| ROE | 17.93% | 484.00% | Weak |
| Net Margin | 28.67% | -71879.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.84 | Strong (Low Leverage) |
| Current Ratio | 6.06 | 5.20 | Strong Liquidity |
| ROA | 14.68% | -27.00% (disorted) | Strong |
PFIZER.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Pfizer Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation